In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632161PMC
http://dx.doi.org/10.3201/eid2712.211772DOI Listing

Publication Analysis

Top Keywords

variants concern
8
limited short-lasting
4
short-lasting virus
4
virus neutralizing
4
neutralizing titers
4
titers induced
4
induced inactivated
4
inactivated sars-cov-2
4
sars-cov-2 vaccine
4
vaccine vitro
4

Similar Publications

Background: The Immunoglobulin Heavy Chain (IGH) genomic region is responsible for the production of circulating antibodies and warrants careful investigation for its association with COVID-19 characteristics. Multiple allelic variants within and across different IGH gene segments form a limited set of haplotypes. Previous studies have shown associations between some of these haplotypes and clinical outcomes of COVID-19.

View Article and Find Full Text PDF

Squamous cell carcinomas in several anatomical sites are caused by human papillomaviruses (HPV), and oncogenic double-stranded DNA viruses. There are about 200 genotypes; HPV16 is the most often occurring variant. Potential ways of infection are skin warts, sexual activity, exposure, immunization, or oral sex.

View Article and Find Full Text PDF

The increasing prevalence of infections due to metallo-β-lactamase (MBL)-producing Enterobacterales poses a serious concern given the limited treatment options available. This systematic literature review (SLR) describes the molecular epidemiology, geographical distribution, and clinical outcomes of such infections. Systematic searches of literature published between January 2013 and May 2023 were performed, and 39 studies with an MBL sample size of ≥25 isolates and ≥2 well-defined outcomes were eligible.

View Article and Find Full Text PDF

A human antibody derived from original SARS-CoV-2 infection effectively neutralizes omicron.

Adv Biotechnol (Singap)

January 2024

Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, 320 Yueyang Road, Shanghai, 200030, China.

SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) Variants of Concern (VOCs), such as the Omicron sub-variants, present significant challenges in pandemic control due to their capacity to escape antibodies and breach vaccine protections. Discovering antibodies that can tolerate mutations in VOCs and understanding their underlying mechanisms is crucial for developing therapeutics for COVID-19 patients, particularly those for whom other therapies may be unsuitable. Here, we report the neutralization of the Omicron variant by FD20, a broadly active human monoclonal antibody.

View Article and Find Full Text PDF

Prenatal gene editing for neurodevelopmental diseases: Ethical considerations.

Am J Hum Genet

January 2025

Department of Social Medicine and Center for Bioethics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Neurodevelopmental diseases (NDDs) are notoriously difficult to treat because clinical symptoms stem from developmental processes that begin before birth. Prenatal gene editing could fill the treatment gap for NDDs by targeting and permanently correcting the genetic variants that underlie these pathogenic developmental processes. At the same time, there is a risk of unintended edits to the fetus or the pregnant person that could result in serious adverse consequences that are difficult, if not impossible, to undo.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!